Literature DB >> 8061281

Neuroprotective effects of riluzole in ALS CSF toxicity.

P Couratier1, P Sindou, F Esclaire, E Louvel, J Hugon.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a neurological disorder neuropathologically characterized by a progressive degeneration of upper and lower motoneurons. The origin of the neuronal death is presently unknown but recent findings suggest that neurodegeneration could be related to an excitotoxic disorder. We have recently shown that the cerebrospinal fluid (CSF) of ALS patients contains for neurones in cultures cytotoxic factors whose toxic properties are mediated by AMPA/kainate receptors, a subgroup of glutamate post-synaptic receptors. This study reports that riluzole partially prevents in vitro the neuronal degeneration produced by ALS CSF (neuronal survival 60.6 +/- 13.1%). Riluzole (5 x 10(-7) M) which reduces excitatory amino acid release, could represent a new pharmacological agent susceptible to be proposed to patients affected by this dramatic neurological disease.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061281     DOI: 10.1097/00001756-199404000-00040

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  8 in total

Review 1.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

2.  Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.

Authors:  G M Ginsberg; B Lev
Journal:  Pharmacoeconomics       Date:  1997-11       Impact factor: 4.981

3.  Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis.

Authors:  H J M van Kan; G J Groeneveld; S Kalmijn; M Spieksma; L H van den Berg; H J Guchelaar
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

4.  Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake.

Authors:  Justin J Yerbury; Mark R Wilson
Journal:  Cell Stress Chaperones       Date:  2009-05-27       Impact factor: 3.667

5.  Conserved genes act as modifiers of invertebrate SMN loss of function defects.

Authors:  Maria Dimitriadi; James N Sleigh; Amy Walker; Howard C Chang; Anindya Sen; Geetika Kalloo; Jevede Harris; Tom Barsby; Melissa B Walsh; John S Satterlee; Chris Li; David Van Vactor; Spyros Artavanis-Tsakonas; Anne C Hart
Journal:  PLoS Genet       Date:  2010-10-28       Impact factor: 5.917

6.  Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole.

Authors:  Sally Liao; Yuleisy Ruiz; Hira Gulzar; Zarina Yelskaya; Lyes Ait Taouit; Murielle Houssou; Trisha Jaikaran; Yuriy Schvarts; Kristina Kozlitina; Upal Basu-Roy; Alka Mansukhani; Shahana S Mahajan
Journal:  PLoS One       Date:  2017-02-23       Impact factor: 3.240

Review 7.  40 Years of CSF Toxicity Studies in ALS: What Have We Learnt About ALS Pathophysiology?

Authors:  Koy Chong Ng Kee Kwong; Pratap K Harbham; Bhuvaneish T Selvaraj; Jenna M Gregory; Suvankar Pal; Giles E Hardingham; Siddharthan Chandran; Arpan R Mehta
Journal:  Front Mol Neurosci       Date:  2021-03-18       Impact factor: 5.639

Review 8.  Cerebrospinal fluid cytotoxicity in amyotrophic lateral sclerosis: a systematic review of in vitro studies.

Authors:  Koy Chong Ng Kee Kwong; Jenna M Gregory; Suvankar Pal; Siddharthan Chandran; Arpan R Mehta
Journal:  Brain Commun       Date:  2020-08-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.